Breast cancer treatment and cognitive function: The current state of evidence, underlying mechanisms and potential treatments

Women's Health

Volumn 5, Issue 5, 2009, Pages 503-516

  Vodermaier, Andrea ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Aromatase inhibitors; Breast cancer; Chemotherapy; Cognitive function; Cortisol; Cytokines; Endocrine therapy; Menopausal status; Tamoxifen

Indexed keywords

ANTINEOPLASTIC AGENT; APOLIPOPROTEIN E; AROMATASE INHIBITOR; CARBOPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; ERYTHROPOIETIN; ESTROGEN; FLUOROURACIL; METHOTREXATE; METHYLPHENIDATE; MODAFINIL; PLACEBO; RALOXIFENE; TAMOXIFEN; THIOTEPA; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADJUVANT THERAPY; ARTICLE; BEHAVIOR THERAPY; BRAIN FUNCTION; BRAIN METABOLISM; BREAST CANCER; BREAST SURGERY; CANCER PATIENT; CANCER RESEARCH; CANCER STAGING; CLINICAL TRIAL; COGNITIVE DEFECT; COGNITIVE THERAPY; EVENT RELATED POTENTIAL; EVIDENCE BASED MEDICINE; FEMALE; GENE MUTATION; HORMONAL THERAPY; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; METHODOLOGY; NEUROIMAGING; NEUROPHYSIOLOGY; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTMENOPAUSE OSTEOPOROSIS; PSYCHOLOGICAL ASPECT; SIDE EFFECT; VERBAL MEMORY; VISUAL MEMORY; WORKING MEMORY; AGED; BREAST NEOPLASMS; CHEMICALLY INDUCED; COGNITION; DRUG EFFECTS; ENDOCRINE SYSTEM; MIDDLE AGED; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AROMATASE INHIBITORS; BREAST NEOPLASMS; COGNITION; COGNITION DISORDERS; ENDOCRINE SYSTEM; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MIDDLE AGED; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 69849112540     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.09.36     Document Type: Article

References (74)

1. Sherwin BB: Estrogen and cognitive functioning in women. Endocrine Rev. 24(2), 133-151 (2003).
2. Ahles TA, Saykin AJ: Candidate mechanisms for chemotherapy-induced cognitive changes. Nat. Rev. Cancer 7(3), 192-201 (2007).
3. Downie FP, Mar Fan HG, Houédé-Tchen N, Yi Q, Tannock IF: Cognitive function, fatigue, and menopausal symptoms in breast cancer patients receiving adjuvant chemotherapy: evaluation with patient interview after formal assessment. Psychooncology 15(10), 921-930 (2006).
4. Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA: The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 100(11), 2292-2299 (2004).
5. Collins B, Mackenzie J, Stewart A, Bielajew C, Verma S: Cognitive effects of chemotherapy in post-menopausal breast cancer patients 1 year after treatment. Psychooncology 18(2), 134-143 (2009).
6. Kreukels BP, van Dam FS, Ridderinkhof KR, Boogerd W, Schagen SB: Persistent neurocognitive problems after adjuvant chemotherapy for breast cancer. Clin. Breast Cancer 8(1), 80-87 (2008).
7. Stewart A, Collins B, Mackenzie J, Tomiak E, Verma S, Bielajew C: The cognitive effects of adjuvant chemotherapy in early stage breast cancer: a prospective study. Psychooncology 17(2), 122-130 (2008).
8. Hermelink K, Untch M, Lux MP et al.: Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. Cancer 109(9), 1905-1913 (2007).
9. Hurria A, Rosen C, Hudis C et al.: Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study. J. Am. Geriatr. Soc. 54(6), 925-931 (2006).
10. van Dam FS, Schagen SB, Muller MJ et al.: Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J. Natl Cancer Inst. 90(3), 210-218 (1998).
11. Ahles TA, Saykin AJ, McDonald BC et al.: Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Res. Treat. 110(1), 143-152 (2008).
12. Schagen SB, van Dam FS, Muller MJ, Boogerd W, Lindeboom J, Bruning PF: Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 85(3), 640-650 (1999).
13. Wieneke MH, Dienst ER: Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psychooncology 4, 61-66 (1995).
14. Bender CM, Sereika SM, Berga SL et al.: Cognitive impairment associated with adjuvant therapy in breast cancer. Psychooncology 15(5), 422-430 (2006).
15. Fan HG, Houédé-Tchen N, Yi QL et al.: Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2 year follow-up of a prospective controlled study. J. Clin. Oncol. 23(31), 8025-8032 (2005).
16. Shilling V, Jenkins V, Morris R, Deutsch G, Bloomfield D: The effects of adjuvant chemotherapy on cognition in women with breast cancer - preliminary results of an observational longitudinal study. Breast 14(2), 142-150 (2005).
17. Castellon SA, Ganz PA, Bower JE, Petersen L, Abraham L, Greendale GA: Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J. Clin. Exp. Neuropsychol. 26(7), 955-969 (2004).
18. Ahles TA, Saykin AJ, Furstenberg CT et al.: Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J. Clin. Oncol. 20(2), 485-493 (2002).
19. Jansen CE, Dodd MJ, Miaskowski CA, Dowling GA, Kramer J: Preliminary results of a longitudinal study of changes in cognitive function in breast cancer patients undergoing chemotherapy with doxorubicin and cyclophosphamide. Psychooncology 17(12), 1189-1195 (2008).
20. Mehlsen M, Pedersen AD, Jensen AB, Zachariae R: No indications of cognitive side-effects in a prospective study of breast cancer patients receiving adjuvant chemotherapy. Psychooncology 18(3), 248-257 (2009).
21. Jenkins V, Shilling V, Deutsch G et al.: A 3 year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br. J. Cancer 94(6), 828-834 (2006).
22. Schagen SB, Muller MJ, Boogerd W, Mellenbergh GJ, van Dam FS: Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients. J. Natl Cancer Inst. 98(23), 1742-1745 (2006).
23. Scherwath A, Mehnert A, Schleimer B et al.: Neuropsychological function in high-risk breast cancer survivors after stem-cell supported high-dose therapy versus standard-dose chemotherapy: evaluation of long-term treatment effects. Ann. Oncol. 17(3), 415-423 (2006).
24. Donovan KA, Small BJ, Andrykowski MA, Schmitt FA, Munster P, Jacobsen PB: Cognitive functioning after adjuvant chemotherapy and/or radiotherapy for early-stage breast carcinoma. Cancer 104(11), 2499-2507 (2005).
25. Cimprich B, Ronis DL: Attention and symptom distress in women with and without breast cancer. Nurs. Res. 50(2), 86-94 (2001).
26. Cimprich B, So H, Ronis DL, Trask C: Pre-treatment factors related to cognitive functioning in women newly diagnosed with breast cancer. Psychooncology 14(1), 70-78 (2005).
27. Schilder CM, Eggens PC, Seynaeve C et al.: Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional findings from the neuropsychological TEAM-side study. Acta Oncol. 48(1), 76-85 (2009).
28. Schagen SB, Hamburger HL, Muller MJ, Boogerd W, van Dam FS: Neurophysiological evaluation of late effects of adjuvant high-dose chemotherapy on cognitive function. J. Neurooncol. 51(2), 159-165 (2001).
29. Kreukels BP, Hamburger HL, de Ruiter MB et al.: ERP amplitude and latency in breast cancer survivors treated with adjuvant chemotherapy. Clin. Neurophysiol. 119(3), 533-541 (2008).
30. Kreukels BP, Schagen SB, Ridderinkhof KR et al.: Effects of high-dose and conventional-dose adjuvant chemotherapy on long-term cognitive sequelae in patients with breast cancer: an electrophysiologic study. Clin. Breast Cancer 7(1), 67-78 (2006).
31. Kreukels BP, Schagen SB, Ridderinkhof KR, Boogerd W, Hamburger HL, van Dam FS: Electrophysiological correlates of information processing in breast-cancer patients treated with adjuvant chemotherapy. Breast Cancer Res. Treat. 94(1), 53-61 (2005).
32. Silverman DH, Dy CJ, Castellon SA et al.: Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy. Breast Cancer Res. Treat. 103(3), 303-311 (2007).
33. Brown MS, Stemmer SM, Simon JH et al.: White matter disease induced by high-dose chemotherapy: longitudinal study with MR imaging and proton spectroscopy. Am. J. Neuroradiol. 19(2), 217-221 (1998).
34. Ferguson RJ, McDonald BC, Saykin AJ, Ahles TA: Brain structure and function differences in monozygotic twins: possible effects of breast cancer chemotherapy. J. Clin. Oncol. 25(25), 3866-3870 (2007).
35. Ahles TA, Saykin AJ, Noll WW et al.: The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology 12(6), 612-619 (2003).
36. Caras I, Grigorescu A, Stavaru C et al.: Evidence for immune defects in breast and lung cancer patients. Cancer Immunol Immunother. 53(12), 1146-1152 (2004).
37. Lyon DE, McCain NL, Walter J, Schubert C: Cytokine comparisons between women with breast cancer and women with a negative breast biopsy. Nurs Res. 57(1), 51-58 (2008).
38. Seruga B, Zhang H, Bernstein LJ, Tannock IF: Cytokines and their relationship to the symptoms and outcome of cancer. Nat. Rev. Cancer 8(11), 887-899 (2008).
39. Sherwin BB, Henry JF: Brain aging modulates the neuroprotective effects of estrogen on selective aspects of cognition in women: a critical review. Front. Neuroendocrinol. 29(1), 88-113 (2008).
40. Espeland MA, Rapp SR, Shumaker SA et al.: Women's Health Initiative Memory Study. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA 291(24), 2959-2968 (2004).
41. Collins B, Mackenzie J, Stewart A, Bielajew C, Verma S: Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study. Psychooncology 18(8), 811-821 (2008).
42. Bender CM, Sereika SM, Brufsky AM et al.: Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer. Menopause 14(6), 995-998 (2007).
43. Eberling JL, Wu C, Tong-Turnbeaugh R, Jagust WJ: Estrogen- and tamoxifen-associated effects on brain structure and function. Neuroimage 21(1), 364-371 (2004).
44. Jenkins V, Shilling V, Fallowfield L, Howell A, Hutton S: Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psychooncology 13(1), 61-66 (2004).
45. Shilling V, Jenkins V, Fallowfield L, Howell T: The effects of hormone therapy on cognition in breast cancer. J. Steroid Biochem. Mol. Biol. 86(3-5), 405-412 (2003).
46. Paganini-Hill A, Clark LJ: Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Res. Treat. 64(2), 165-176 (2000).
47. Buckwalter JG, Geiger AM, Parsons TD, Handler J, Howes J, Lehmer RR: Cognitive effects of short-term use of raloxifene: a randomized clinical trial. Int. J. Neurosci. 117(11), 1579-1590 (2007).
48. Yaffe K, Krueger K, Sarkar S et al.: Cognitive function in postmenopausal women treated with raloxifene. N. Engl. J. Med. 344(16), 1207-1213 (2001).
49. Haskell SG, Richardson ED: The effect of raloxifene on cognitive function in postmenopausal women: a randomized clinical trial. Conn. Med. 68, 355-358 (2004).
50. Nickelsen T, Lufkin EG, Riggs BL, Cox DA, Crook TH: Raloxifene hydrochloride, a selective estrogen receptor modulator: safety assessment of effects on cognitive function and mood in postmenopausal women. Psychoneuroendocrinology 24(1), 115-128 (1999).
51. Yaffe K, Krueger K, Cummings SR et al.: Effects of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) trial. Am. J. Psychiatry 162, 683-690 (2005).
52. Hermelink K, Henschel V, Untch M, Bauerfeind I, Lux MP, Munzel K: Short-term effects of treatment-induced hormonal changes on cognitive function in breast cancer patients: results of a multicenter, prospective, longitudinal study. Cancer 113(9), 2431-2439 (2008).
53. Jenkins VA, Ambroisine LM, Atkins L, Cuzick J, Howell A, Fallowfield LJ: Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II). Lancet Oncol. 9(10), 953-961 (2008).
54. Sherwin BB, Tulandi T: 'Add-back' estrogen reverses cognitive deficits induced by a gonadotropin-releasing hormone agonist in women with leiomyomata uteri. J. Clin. Endocrinol. Metab. 81(7), 2545-2549 (1996).
55. Palomba S, Orio F Jr, Russo T, Falbo A, Amati A, Zullo F: Gonadotropin-releasing hormone agonist with or without raloxifene: effects on cognition, mood, and quality of life. Fertil. Steril. 82(2), 480-482 (2004).
56. Grigorova M, Sherwin BB, Tulandi T: Effects of treatment with leuprolide acetate depot on working memory and executive functions in young premenopausal women. Psychoneuroendocrinology 31(8), 935-947 (2006).
57. Ernst T, Chang L, Cooray D et al.: The effects of tamoxifen and estrogen on brain metabolism in elderly women. J. Natl Cancer Inst. 94(8), 592-597 (2002).
58. Ciriza I, Carrero P, Azcoitia I, Lundeen SG, Garcia-Segura LM: Selective estrogen receptor modulators protect hippocampal neurons from kainic acid excitotoxicity: differences with the effect of estradiol. J. Neurobiol. 61(2), 209-221 (2004).
59. O'Shaughnessy JA, Vukelja SJ, Holmes FA et al.: Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy. Clin. Breast Cancer 5(6), 439-446 (2005).
60. Fan HG, Park A, Xu W et al.: The influence of erythropoietin on cognitive function in women following chemotherapy for breast cancer. Psychooncology 18(2), 156-161 (2009).
61. Mar Fan HG, Clemons M, Xu W et al.: A randomised, placebo-controlled, double-blind trial of the effects of D-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer. Support Care Cancer 16(6), 577-583 (2008).
62. Kohli S, Fisher SG, Tra Y et al.: The effect of modafinil on cognitive function in breast cancer survivors. Cancer 115(12), 2605-2616(2009).
63. Ferguson RJ, Ahles TA, Saykin AJ et al.: Cognitive-behavioral management of chemotherapy-related cognitive change. Psychooncology 16(8), 772-777 (2007).
64. Cruess DG, Antoni MH, McGregor BA et al.: Cognitive-behavioral stress management reduces serum cortisol by enhancing benefit finding among women being treated for early stage breast cancer. Psychosom. Med. 62(3), 304-308 (2000).
65. McGregor BA, Antoni MH, Boyers A, Alferi SM, Blomberg BB, Carver CS: Cognitive-behavioral stress management increases benefit finding and immune function among women with early-stage breast cancer. J. Psychosom. Res. 56(1), 1-8 (2004).
66. Heuser I, Lammers CH: Stress and the brain. Neurobiol. Aging 24(Suppl. 1), S69-S76 (2003).
67. Hellhammer J, Schlotz W, Stone AA, Pirke KM, Hellhammer D: Allostatic load, perceived stress, and health: a prospective study in two age groups. Ann. NY Acad. Sci. 1032, 8-13 (2004).
68. Wolf OT, Kuhlmann S, Buss C, Hellhammer DH, Kirschbaum C: Cortisol and memory retrieval in humans: influence of emotional valence. Ann. NY Acad. Sci. 1032, 195-197 (2004).
69. Vearncombe KJ, Pachana NA: Is cognitive functioning detrimentally affected after early, induced menopause? Menopause 16(1), 188-198 (2009).
70. Ouimet LA, Stewart A, Collins B, Schindler D, Bielajew C: Measuring neuropsychological change following breast cancer treatment: an analysis of statistical models. J. Clin. Exp. Neuropsychol. 31(1), 73-89 (2009).
71. Schagen SB, Muller MJ, Boogerd W et al.: Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. Ann. Oncol. 13(9), 1387-1397 (2002).
72. Tchen N, Juffs HG, Downie FP et al.: Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J. Clin. Oncol. 21(22), 4175-4183 (2003).
73. Brezden CB, Phillips KA, Abdolell M, Bunston T, Tannock IF: Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J. Clin. Oncol. 18(14), 2695-2701 (2000).
74. Debess J, Ostergaard Riis J, Pedersen L, Ewertz M: Cognitive function and quality of life after surgery for early breast cancer in North Jutland, Denmark. Acta Oncol. 19, 1-9 (2008).